Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$3.23 USD
+0.01 (0.31%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $3.24 +0.01 (0.31%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
XERS 3.23 +0.01(0.31%)
Will XERS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for XERS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XERS
Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
XERS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q2 Earnings Expected to Decline
Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
Other News for XERS
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips +
Xeris Biopharma: Time For A Reassessment
Xeris to Participate in Upcoming Investor Conferences
More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying